Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Invested Capital (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Invested Capital for 4 consecutive years, with $43.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 5.37% to $43.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $43.7 million, a 5.37% decrease, with the full-year FY2024 number at $33.0 million, down 51.56% from a year prior.
  • Invested Capital was $43.7 million for Q3 2025 at Orchestra BioMed Holdings, up from $295000.0 in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $99.8 million in Q1 2023 to a low of $78000.0 in Q1 2022.
  • A 4-year average of $51.6 million and a median of $54.6 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 127787.18% in 2023, then crashed 99.33% in 2025.
  • Orchestra BioMed Holdings' Invested Capital stood at $54.6 million in 2022, then increased by 24.57% to $68.0 million in 2023, then tumbled by 51.56% to $33.0 million in 2024, then soared by 32.71% to $43.7 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Invested Capital are $43.7 million (Q3 2025), $295000.0 (Q2 2025), and $16.9 million (Q1 2025).